Drug Database
PA

pantoprazole

✓ Approved

Nanodaru · ATP4A · Small Molecule

What is pantoprazole?

pantoprazole is a small molecule developed by Nanodaru. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

CompanyNanodaru
Drug ClassSmall Molecule
Molecular TargetATP4A
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Nanodaru

Mechanism of Action

Molecular Targets

pantoprazole acts on 1 molecular target:

ATP4AATPase H+/K+ transporting subunit alpha (ATP6A)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

pantoprazole is developed for 4 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Gastrointestinal disordersDuodenal ulcer✓ Approved
Gastrointestinal disordersGastric ulcer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Gastrinoma✓ Approved
Gastrointestinal disordersGastrooesophageal reflux disease✓ Approved

Related Research Articles

PubMedNeurogastroenterology and motility2026-11-10

Targeting the Gut-Brain Axis in Functional Dyspepsia: Buspirone and Mirtazapine Improve Anxiety and PAGI-SYM Scores.

Khorashadizadeh Mahdieh M, Salmani Fatemeh F, Tavakoli Tahmine T

Functional dyspepsia is a chronic gastrointestinal disorder with uncertain causes, often linked to anxiety and depression, which can worsen symptoms and hinder treatment success. Although psychological therapies and antidepressants have shown some benefit, the role of anti-anxiety medications remains unclear. This study aims to evaluate the effectiveness of buspirone and mirtazapine in reducing symptoms and improving the quality of life for patients with functional dyspepsia. In a semi experimental study, 71 patients with functional dyspepsia were randomized to receive either buspirone 15 mg, mirtazapine 7.5 mg, or pantoprazole 40 mg once daily for 12 weeks. Outcomes-anxiety severity, dyspepsia symptom score, quality of life, and adverse events-were assessed at baseline and monthly. Efficacy was analyzed by repeated-measures ANOVA and adverse event rates by chi-square tests. Both buspirone and mirtazapine significantly outperformed pantoprazole alone in reducing anxiety (buspirone vs. control at 3 months, p = 0.01; both active treatments vs. control, p < 0.05) and in alleviating functional dyspepsia symptoms by Week 12 (both vs. control, p < 0.05), with no difference between the two active drugs. This study suggests that buspirone and mirtazapine are effective in reducing anxiety and improving symptoms in patients with functional dyspepsia. These findings highlight the potential role of anti-anxiety medications in managing both the psychological and gastrointestinal aspects of this disorder.

PMID 43004923
Read full article →
PubMedMolecular neurobiology2026-11-06

Effects of Pantoprazole on PTZ-Kindling Progression and Associated Neuroinflammatory and Endoplasmic Reticulum Stress Responses in Rats.

Taşkıran Ahmet Şevki AŞ, Joha Ziad Z, Özkaraca Mustafa M, Ataseven Hilmi H

Epileptogenesis is characterized by complex molecular changes, including neuroinflammation, endoplasmic reticulum (ER) stress, and apoptosis, contributing to seizures and associated cognitive and behavioral impairments. Pantoprazole, a proton pump inhibitor, has demonstrated anti-inflammatory and neuroprotective properties. This study investigated its effects on PTZ-kindling progression and associated molecular alterations in a pentylenetetrazole (PTZ)-induced rat model. Adult male Wistar albino rats (n = 30) were subjected to chronic PTZ kindling (30 mg/kg, i.p., on alternate day, 15 injections). Pantoprazole (5 and 10 mg/kg) or valproic acid (150 mg/kg) was administered prior to PTZ. Seizure severity was scored using the Racine scale. Cognitive and anxiety-like behaviors were assessed by passive avoidance and open field tests. Neuroinflammatory (TNF-α, NF-κB, IL-1β, COX-1/2), ER stress (GRP78, ATF4, CHOP), and apoptotic (caspase-3/9) markers were measured by ELISA in cortex and hippocampus. NF-κB, iNOS, and p-NMDAR2B expression in hippocampal CA1 and CA3 regions were evaluated immunohistochemically. Histopathological analysis was also performed. PTZ significantly increased seizure severity, memory impairment, and anxiety-like behavior, alongside elevated neuroinflammatory, ER stress, and apoptotic markers. Increased NF-κB, iNOS, and p-NMDAR2B expression and neuronal degeneration were observed in hippocampal regions. Pantoprazole dose-dependently attenuated PTZ-kindling progression, improved behavioral outcomes, and reduced the measured molecular alterations. Histopathological and immunohistochemical findings confirmed decreased neuronal damage and marker expression. Pantoprazole demonstrated protective effects in the PTZ-kindling model, which may be associated with modulation of neuroinflammatory, ER stress, apoptotic, and NMDAR2B-related pathways. These findings suggest that pantoprazole warrants further investigation as a potential adjunctive therapeutic strategy for epilepsy.

PMID 42988973
Read full article →
PubMedSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026-11-04

Proton pump inhibitors in prevention of cisplatin-induced nephrotoxicity: a systematic review.

Pakkhesal Sina S, Mohammadi Pouya P, Rezagholizadeh Afra A, Koochaki Zahra Z et al.

Cisplatin is a cornerstone of chemotherapy, but its clinical utility is limited by dose-dependent nephrotoxicity. Proton pump inhibitors (PPIs) have been hypothesized to prevent this toxicity by inhibiting the renal transporter OCT2, a key mediator of cisplatin uptake into tubular cells. However, independent evidence links PPIs to acute kidney injury (AKI). This systematic review aimed to synthesize the evidence on the efficacy and safety of PPI co-administration for preventing cisplatin-induced nephrotoxicity. PubMed, Embase, Web of Science, and Scopus were systematically searched for studies comparing cisplatin therapy with PPI co-administration versus cisplatin without PPIs. Randomized controlled trials (RCTs) and observational studies reporting renal outcomes were included. Study quality was assessed using the Cochrane RoB2 tool for RCTs and the ROBINS-I tool for observational studies. Due to extreme clinical, methodological, and statistical heterogeneity, a structured narrative synthesis was performed instead of a quantitative meta-analysis. The study was registered at PROSPERO (CRD420251087906). Eight studies (n = 1062 participants) were included (two RCTs and six non-randomized studies). Two retrospective cohorts reported a significant nephroprotective effect. One RCT showed a trend toward protection in its primary endpoint (0% nephrotoxicity in high-dose pantoprazole vs 25% in control, p = 0.078), with significant suppression of renal injury biomarkers. Conversely, one prospective cohort identified PPI use as an independent risk factor for AKI (OR 2.78; p = 0.010) and worse post-treatment eGFR outcomes. Four additional studies (one crossover RCT, three retrospective) found no statistically significant association between PPI use and renal outcomes. Current evidence does not allow a clear conclusion regarding the safety or efficacy of PPIs in this setting. While theoretically beneficial, clinical data reveals conflicting results and a potential signal for increased AKI risk. PPIs may reduce gastrointestinal toxicity, but caution is warranted due to a potential signal for harm. Further high-quality RCTs are needed to provide a definitive answer.

PMID 42980842
Read full article →
PubMedJournal of voice : official journal of the Voice Foundation2026-11-04

Effects of Pharmacological Antireflux Therapy on Voice Outcomes in Patients with Laryngopharyngeal Reflux: A Systematic Review and Meta-Analysis.

Llorente-Santiago Mercedes M, Sosa Reina María Dolores MD, Velázquez Saornil Jorge J, da Casa Carmen C

Laryngopharyngeal reflux (LPR) is associated with dysphonia, but the effect of antireflux pharmacological treatment on voice outcomes remains controversial. This meta-analysis assessed whether proton pump inhibitors, alone or in combination with alginates, produce measurable improvements in voice in patients with LPR. A systematic review and meta-analysis was conducted in accordance with PRISMA and registered in PROSPERO (CRD420251063917). PubMed, Web of Science, and Scopus were searched up to 28 February 2026. Quantitative studies reporting pre- and posttreatment measures in patients with LPR and multidimensional voice outcomes were included: the Voice Handicap Index (VHI), acoustic parameters (jitter, shimmer, and noise-to-harmonic ratio (NHR)), and perceptual assessment using GRBAS. Risk of bias was assessed with the revised JBI tool for quasi-experimental studies, and certainty of evidence with GRADE. Random-effects model meta-analyses were performed. Five studies involving 257 patients were included. The treatment duration was 12 weeks in all cases; four studies used pantoprazole and one used omeprazole. Antireflux treatment significantly reduced the VHI (MD = -7.63; 95% CI: -9.48 to -5.79; P < 0.001; I² = 30%). Jitter (MD = -0.31; 95% CI: -0.49 to -0.13; P < 0.001; I² = 0%) and shimmer (MD = -0.81; 95% CI: -1.23 to -0.39; P < 0.001; I² = 19%) also improved. No significant changes were observed in NHR (MD = -0.01; P > 0.05). In perceptual assessment, overall grade of dysphonia (MD = -0.27; P < 0.001) and roughness (MD = -0.23; P < 0.001) improved, but not breathiness, asthenia, and strain. Based on low-certainty evidence, antireflux pharmacological therapy may be associated with small but consistent improvements in selected voice dimensions in patients with LPR, particularly in patient-reported outcomes, acoustic perturbation measures, and perceptual parameters. However, not all voice dimensions showed significant changes after treatment, supporting a multidimensional approach and the need for larger controlled trials.

PMID 42982683
Read full article →
PubMedWiener medizinische Wochenschrift (1946)2026-11-03

Histological disappearance of persistent clarithromycin-resistant Helicobacter pylori infection following administration of a sulforaphane-, curcumin- and Lactobacillus-containing food supplement: a case report.

Fischler Nikolaus N

Increasing antimicrobial resistance has become a major challenge in the treatment of Helicobacter pylori infection. Sulforaphane, a bioactive isothiocyanate derived from broccoli sprouts, has demonstrated anti-H. pylori activity in experimental and clinical studies. Curcumin and probiotic bacteria have also been investigated as adjunctive therapies. A woman in her seventies underwent upper gastrointestinal endoscopy screening. Histology revealed chronic active Helicobacter pylori-associated gastritis involving the antrum and corpus. Molecular testing confirmed H. pylori infection and detected the clarithromycin resistance mutation A2143G in the 23S rRNA gene. Following treatment with bismuth quadruple therapy consisting of Pylera® (Laboratoires Juvise Pharmaceuticals, France: bismuth subcitrate potassium 140 mg, metronidazole 125 mg and tetracycline hydrochloride 125 mg per capsule; three capsules four times daily) plus pantoprazole (40 mg twice daily for 10 days, followed by pantoprazole 40 mg once daily for 4 weeks), repeat endoscopy 1 year later demonstrated persistent active gastritis and persistence of the resistance mutation. The patient subsequently received a nutraceutical preparation containing broccoli-derived sulforaphane, curcumin, and Lactobacillus acidophilus. The preparation was administered as two capsules twice daily before meals for 21 days. Follow-up endoscopy approximately 3 months later demonstrated resolution of inflammatory activity and the absence of detectable H. pylori organisms in antral and corpus biopsies. This case documents the histological disappearance of persistent clarithromycin-resistant H. pylori infection following administration of a sulforaphane-, curcumin- and probiotic-containing nutraceutical. Although causality cannot be established from a single observation, the findings support further investigation of such interventions in patients with treatment-refractory infection.

PMID 42975778
Read full article →
PubMedPharmacogenomics2026-10-30

Prescribing prevalence and trends of medications with pharmacogenetic implications: a study based on primary care data in Manitoba, Canada.

Aziz Md Abdul MA, Kosowan Leanne L, Hasan Mahin M, Liang Vincent V et al.

To characterize prescribing prevalence and temporal trends of medications with pharmacogenetic (PGx) implications in Manitoba primary care and identify frequently implicated pharmacogenes. We conducted a retrospective, repeated annual analysis of electronic medical record data from the Manitoba Primary Care Research Network (MaPCReN) between 2017 and 2021. Prescribing patterns and unadjusted relative risks (RRs) according to demographic characteristics were assessed. Among 223,630 eligible patients, 42.4% received ≥ 1 medication with PGx implications. Greater exposure was observed among adults aged ≥ 65 years (RR 1.75, 95% CI 1.74-1.77), females (RR 1.24, 95% CI 1.23-1.26), and rural residents (RR 1.23, 95% CI 1.22-1.25) (all p < 0.0001). The aggregate prescribing prevalence of the 10 most common medications with clinically actionable PGx recommendations decreased by 8.0% from 2017 to 2021 (p < 0.001). Pantoprazole (+55.4%) and sertraline (+30.0%) increased, whereas codeine (-33.2%), citalopram (-26.5%), and omeprazole (-20.6%) declined. Frequently implicated pharmacogenes included CYP2D6, CYP2C19, CYP2B6, SLCO1B1, and ABCG2. Medications with PGx implications were commonly prescribed within MaPCReN. These patterns may inform future studies evaluating PGx testing in Manitoba primary care.

PMID 42960703
Read full article →

+2429 more articles available with a free account

Sign up free to view all articles →

Ask about pantoprazole